Cardiff Oncology (CRDF) investor relations material

Executive summary

• Focused on developing onvansertib, a PLK1 inhibitor, for RAS-mutated metastatic colorectal cancer (mCRC) and other cancers, with multiple ongoing clinical trials and collaborations with academic centers.

• Completed successful End-of-Phase 2 meeting with FDA, aligning on Phase 3 trial design for onvansertib in first-line RAS-mutated mCRC.

• Announced positive Phase 2 data: 30 mg onvansertib + FOLFIRI/bev arm showed 72.2% ORR vs. 43.2% for standard of care.

• Announced new executive appointments, including a new CEO, CFO, and COO, to strengthen leadership and support clinical and regulatory milestones.

• Presented promising clinical and preclinical data at major conferences, supporting the efficacy and safety of onvansertib in various cancer indications.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $46.1 million as of March 31, 2026.

• Revenue for Q1 2026 was $41,000, down from $109,000 in Q1 2025, primarily from royalties unrelated to onvansertib.

• Net loss for Q1 2026 was $12.3 million, an improvement from $13.4 million in Q1 2025.

• Net cash used in operating activities was $12.3 million for Q1 2026, down from $12.8 million in Q1 2025.

• Total operating expenses decreased to $12.9 million from $14.5 million year-over-year, mainly due to lower R&D costs.

Outlook and guidance

• Current capital resources are expected to fund operations into Q1 2027, but not for the full 12 months following the report date, raising substantial doubt about the ability to continue as a going concern.

• Additional funding will be required to support ongoing clinical programs and operations.

• Additional Phase 3 trial details and regulatory strategy to be shared by mid-2026.